Proton arc therapy reduces the dose delivered to circulating blood compared to intensity-modulated proton therapy for head-and-neck cancer.

Authors

Sebastian Tattenberg, Peilin Liu, Xiaoda Cong, Cornelia Hoehr, Xuanfeng Ding

Published in

Journal of applied clinical medical physics. Volume 27. Issue 11. Pages e70864.

Abstract

Compared to intensity-modulated proton therapy (IMPT), proton arc therapy (PAT) has various dosimetric advantages. However, questions have been raised over whether the larger low-dose bath during PAT may increase radiation-induced lymphocyte killing, which is correlated with adverse clinical outcomes.
The purpose of this study is to quantitatively compare radiation dose delivery to circulating blood during IMPT and PAT.
For each of 10 head-and-neck cancer patients, one IMPT and one PAT treatment plan were created, and the hematological dose (HEDOS) blood dose model was used to simulate radiation dose delivery to circulating blood. HEDOS simulations utilized gantry angle-wise dose distributions (including for PAT) and considered gantry rotation and energy layer switching as well as irradiation times. Blood dose histograms as well as the mean dose to all simulation blood particles (D_mean) and the dose delivered to the 90% and 10% of blood particles receiving the highest dose (D_90% and D_10%) were then compared between IMPT and PAT.
For IMPT, blood dose metrics (in the form of mean over all patients ± one standard deviation) were (0.522 ± 0.204)Gy(RBE) for D_90%, (0.563 ± 0.212)Gy(RBE) for D_mean, and (0.605 ± 0.219)Gy(RBE) for D_10%. For PAT, D_90% was (0.430 ± 0.184)Gy(RBE), D_mean was (0.483 ± 0.195)Gy(RBE), and D_10% was (0.538 ± 0.207)Gy(RBE). The Wilcoxon signed-rank test indicated statistically significant (p < 0.05) differences between blood dose metrics of IMPT and PAT for all patients, and IMPT did not increase the percentage of blood particles which received no radiation dose during the delivery of a single treatment fraction.
Compared to IMPT, proton arc therapy was associated with significantly lower radiation dose delivery to circulating blood across a variety of different metrics. Proton arc therapy for head-and-neck cancer is therefore not expected to result in higher radiation-induced killing of circulating lymphocytes compared to IMPT.

PMID:
42900560
Bibliographic data and abstract were imported from PubMed on 21 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.